Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 3/20 | 0.47 |
| ▸ | MAOB | P27338 | 3/20 | 0.47 |
| ▸ | CA2 | P00918 | 8/20 | 0.44 |
| ▸ | CA1 | P00915 | 5/20 | 0.44 |
| ▸ | CA9 | Q16790 | 4/20 | 0.44 |
| ▸ | CA5A | P35218 | 1/20 | 0.44 |
| ▸ | HTR7 | P34969 | 4/20 | 0.40 |
| ▸ | CA12 | O43570 | 2/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL635599 | 0.92 | MAOA (0.50) | MAOAMAOBCA2CA1CA9 | |
| SCHEMBL4977014 | 0.74 | CYP3A4 (0.41) | CA2CA1CA5ACA7 | |
| SCHEMBL4978909 | 0.74 | CA1 (0.39) | CA2CA1CA9CA12CA7 | |
| SCHEMBL15017279 | 0.73 | MAOA (0.45) | MAOAMAOBCA2CA1CA9 | |
| SCHEMBL4980605 | 0.73 | CHRNA7 (0.43) | CA2 | |
| SCHEMBL30627040 | 0.71 | CTSL (0.40) | CA2CA1CA9CA12CA7 | |
| SCHEMBL6124771 | 0.70 | CA2 (0.49) | CA2CA1CA9CA5ACA12 | |
| SCHEMBL5190756 | 0.70 | MAOA (0.83) | MAOAMAOBKDM1A | |
| SCHEMBL156160 | 0.69 | MAOA (0.54) | MAOAMAOBGAAKDM1A | |
| Hydrochloric Acid SCHEMBL3712837 | 0.68 | MAOA (0.79) | MAOAMAOBKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118323-A1 | ANTITUMOR BENZOYLSULFONAMIDES | MADER MARY MARGARET | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118323-A1 | ANTITUMOR BENZOYLSULFONAMIDES | HCCS, GLS2, GLS | MAOA 3948/4885MAOB 2627/4885CA2 1594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.